REGISTERED NUMBER: 15498193 (England and Wales)

Unaudited Financial Statements

for the Period 17 February 2024 to 31 December 2024

for

Gillpharm Property Investments Ltd

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTOR:

Mr Daljit Singh Gill

REGISTERED OFFICE:

Office 1

21 Hatherton Street

Walsall

West Midlands

WS4 2LA

REGISTERED NUMBER:

15498193 (England and Wales)

ACCOUNTANTS:

Dhillon Accountants Limited

Chartered Accountants

Office 1

21 Hatherton Street

Walsall

WS4 2LA

FIXED ASSETS

Tangible assets

4

965,605

CURRENT ASSETS

Cash at bank and in hand

11,326

CREDITORS

Amounts falling due within one year

5

(216,912

)

NET CURRENT LIABILITIES

(205,586

)

TOTAL ASSETS LESS CURRENT LIABILITIES

760,019

CREDITORS

Amounts falling due after more than one year

6

(786,654

)

NET LIABILITIES

(26,635

)

CAPITAL AND RESERVES

Called up share capital

100

Retained earnings

(26,735

)

SHAREHOLDERS' FUNDS

(26,635

)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 30 September 2025 and were signed by:

Mr Daljit Singh Gill - Director

1.	STATUTORY INFORMATION

Gillpharm Property Investments Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Going concern

The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 .

4.	TANGIBLE FIXED ASSETS

Land and

buildings

£

COST

Additions

965,605

At 31 December 2024

965,605

NET BOOK VALUE

At 31 December 2024

965,605

5.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Bank loans and overdrafts

76,060

Other creditors

140,852

216,912

6.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

£

Bank loans

786,654

7.	RELATED PARTY DISCLOSURES

Included in other creditors are the balances due to the companies mentioned below as at 31 December 2024:

- Pyramid Pharma 10 Limited - £35,063

- Gillpharm Limited - £103,650

The all above loans are interest free and repayable on demand.

Mr Daljit Singh Gill is the director of above mentioned companies as at 31 December 2024.

8.	ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Mr Daljit Singh Gill.